Lilly has unveiled promising results from a Phase III study of a lung cancer treatment which showed improved overall survival in patients. The news is a welcome relief to Lilly, which has endured ...
Hosted on MSN1mon
Lilly reports positive Phase 3 breast cancer data for imlunestrantThe study will continue to assess overall survival as a secondary endpoint, Lilly said. The data will be presented Wednesday at the 2024 San Antonio Breast Cancer Symposium and published ...
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback